Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

M7824

- PMLiVE

EMA starts review of Pfizer and Merck’s PD-L1 inhibitor

Avelumab looks set to be the first new drug to treat Merkel cell carcinoma

- PMLiVE

Merck completes €15m Spanish biotech facility expansion

Enlarged Tres Cantos site will help meet demand for fertility and growth hormone drugs

- PMLiVE

Merck sees €2bn from new launches by 2022

Expects to deliver total sales of €4bn with multiple sclerosis, fertility and cancer drugs portfolio

- PMLiVE

NICE rejects Imbruvica for non-Hodgkin’s lymphoma

Draft guidance cites insufficient cost-effectiveness evidence for J&J’s drug

- PMLiVE

Merck KGaA appoints chief strategy officer

Isabel De Paoli will take up the role from 1 October

Shire Basingstoke

Shire gives up on Momenta-partnered Humira biosimilar

Will fund programme for another 12 months while divesting ongoing activities to Momenta

- PMLiVE

Novartis seeks first-line use for lung cancer drug Zykadia

Looks to go head-to-head with Pfizer/Merck KGaA’s Xalkori and Roche’s Alecensa

- PMLiVE

NICE backs Xalkori for lung cancer, but may cut two others from CDF

Preliminary verdict could lead to removal of Novartis' Afinitor and Janssen's Imbruvica from the Fund

- PMLiVE

EMD Serono president James Hoyes joins consultants RxC

Takes up a role as executive partner at the US management consulting firm

- PMLiVE

Fertility drugs drive healthcare growth at Merck KGaA

Strong performances from Gonal-f and Rebif boost the firm’s 2016 sales forecast

Roche Basel Switzerland

Roche’s Gazyvaro cleared for follicular lymphoma in Europe

Second indication anticipated to increase peak sales by up to $1bn

Merck’s accelerator to take start-ups to Silicon Valley

Will expand the reach of its Darmstadt and Nairobi programmes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links